Implementing Leadership Change
Gene One is a privately owned biotechnology company seeking an initial public offering (IPO). Before transitioning into an IPO company, the Chief Executive Officer, Don Ruiz should consider various options in deciding Gene One’s future. Team A has provided two strategies to help Ruiz in making the correct decision for his company. Strategy one suggests Gene One to continue to work as it is currently, research, and develops more products that Gene One would benefit from in the future. The second strategy focuses on the transition of Gene One becoming an IPO company.
Implementation of Remaining with the Current Strategy
Gene One has grown ...view middle of the document...
Gene One can use performance objectives “to guide planning and facilitate evaluation progress, but the focus of a vision should be on values and ideological themes, not on improvement of economic outcomes or outperforming rivals” (Yukl, 2010, p. 311). Performance objectives can set goals to achieve the organization’s objectives when it is included in their vision (Yukl, 2010).
Gene One has and will continue to be an innovative leader in the biotech world creating plants that grow two times more rapidly with a reduced amount of pesticides and that taste better. Teri Robertson, the Chief Technology Officer, won the CTO of the year. This distinguished award reflects the direction and motivation of Gene One and its employees. The location of Gene One allows testing in every type of climate by the same testers. This will permit a consolidated consensus by the researchers when analyzing test results, growth patterns and changes. By continuing under the same strategy and leadership that has made Gene One a world leader in biotechnology the organization will be able to continue operations without major changes to structure and leadership. This strategy has grown a two million dollar business to a 400 million dollar business in a short eight years. The current operation and leadership program is proven to be successful and should remain in effect.
Implementation of Going Public Current Strategy
The going public process of an organization is very time consuming and expensive. However, if the company is successful, the company will tremendously benefit from the revenue and growth of the company generated from the IPO. Although growth is beneficial to the Gene One, there are advantages and disadvantages that occur by the process of Gene One transitioning from a private to public company.
There are numerous advantages for Gene One going public. The first is the financial benefit earned from the increase capital. Capital can be used to fund research and development, fund capital expenditure or even used to pay off existing debt (Taubman, n.d.). In addition to an increase in capital and once the shares of Gene One are traded publically, the shares are now considered to have a market value can be resold. In addition, public companies are more known to the public and this enables Gene One to obtain a larger market and produce more investors.
There are numerous disadvantages for Gene One to go public. First, conducting an IPO is time consuming and expensive. A successful IPO can take up to a year or more to complete (Taubman, n.d.). In addition, Gene One can expect to spend an excess of sums on attorneys, accountants, and underwriter’s fees. Once Gene One becomes a publically traded company, it will register with the Securities Exchange Act of 1934 (SEC) and regulated by the SEC. Therefore, Gene One must meet the rules and regulations monitored by the SEC. The SEC requires public companies to make financial...